science
To sponsor this category, click here | subscribe to this category

A balanced approach to Avandia data

-there is not enough evidence to say Actos is any safer than Avandia. – given that there are no head to head studies comparing the two, comparing separate, retrospective studies is not good practice and best avoided (this is precisely what Dr

Is the Critical Path Initiative in Critical Condition? Is the Advancing Regulatory Science Initiative Replacing the Critical Path?

Does anyone remember the FDA's Critical Path Initiative (CPI)?

Sources: AB Science readies $70M IPO

Reuters is reporting that France’s AB Science is preparing to float an IPO designed to raise $70 million.

FDA Should Begin a Collaborative Wiki to Innovate More Quickly

BIND rounds up $11M, names new CEO

BIND Biosciences, a 2008 Fierce 15 winner , announced today that it has raised $11 million in Series C financing. The company also said that it’s hired

Dealmaking reaches fever pitch at year’s end

The emerging biotech business model typically follows a predictable course: Move your lead therapy through trials to the point at which you can gather positive proof-of-concept data, score a licensing deal. Turn to the next program and repeat. If you’re really good at the science and lucky with the results, you get more investment cash and the eventual opportunity to pick between an IPO or a buyout.

Another Blogroll Update

Time for some more useful sites! In the blog category, welcome to Intermolecular , Natural Product Man , Experimental Error . And in the chemistry data section, I’ve added Synthetic Pages , Not Voodoo , and the Organic Chemistry Portal .

BioVex snags $30M to pay for pivotal trial

A week after putting out the final data on its successful mid-stage cancer trial for OncoVex, BioVex has fattened its bank account with $30 million in fresh venture funds from a slate of new investors, bringing its total take for the year to a whopping $70 million. The war chest will pay for a late-stage trial of the promising oncology program and give BioVex CEO Philip Astley-Sparke plenty of time to work on a licensing deal. OncoVex takes an oncolytic virus and attaches it to a therapy designed to spur the immune system, essentially dispatching tumor-killers on a search and destroy mission.

GenVec wins $22M vax development contract

GenVec is on a roll. A day after winning an orphan drug designation

New Merck in the hunt for biotech buyouts, new pacts

Merck CEO Richard Clark went to some pains